Skip to main content
. Author manuscript; available in PMC: 2015 Dec 28.
Published in final edited form as: Int J Cancer. 2013 Mar 13;133(5):1101–1106. doi: 10.1002/ijc.28115

Table 2.

Population prevalence of HPV, as detected by LA conducted without or with triage by a positive HC-2 test among women aged 14–59 years—USA, 2003–2006

HPV types Population prevalence
detected by LA conducted
on all specimens
(without triage)
% (95% CI)		 Population prevalence
detected by LA conducted
on the subset of specimens
positive by HC-2 (with triage)
% (95% CI)
Oncogenic HPV vaccine types (HPV 16, 18) 6.2 (5.4–7.1) 2.4 (1.9–3.0)
HPV vaccine types (HPV 6, 11, 16, 18) 8.8 (7.8–10.0) 3.0 (2.5–3.6)
Oncogenic HPV types detected by HC-2
 (HPV 16, 18, 31, 33, 35, 39,
 45, 51, 52, 56, 58, 59, 66, 68)		 23.7 (21.6–26.0) 7.3 (6.4–8.2)